(Q28239752)

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

The genetics of multiple sclerosis and its experimental models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Infectious causes of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Disturbed regulatory T cell homeostasis in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Th17 Cells and autoimmune encephalomyelitis (EAE/MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Mechanisms of action of interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Disruption of central nervous system barriers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Molecular mechanisms of axonal damage in inflammatory central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Axonal pathology in multiple sclerosis: relationship to neurologic disability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Distinct and Nonredundant In Vivo Functions of IFNAR on Myeloid Cells Limit Autoimmunity in the Central Nervous System

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Decreased integrin gene expression in patients with MS responding to interferon-beta treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

In vitro modulation of adhesion molecules, adhesion phenomena, and fluid phase endocytosis on human umbilical vein endothelial cells and brain-derived microvascular endothelium by IFN-beta 1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon beta-1a and TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interferon-beta is neuroprotective against the toxicity induced by activated microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Gene expression analysis of interferon-beta treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591110-000000000-00000

Interferon-beta is a potent promoter of nerve growth factor production by astrocytes

21 January 2018

1 reference

12 December 2020

Interferon β-1a downregulates TNFα-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway

1 reference

12 December 2020

Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta

1 reference

12 December 2020

Identification of macrophage populations expressing tumor necrosis factor-alpha mRNA in acute multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Possibility of inducing anterior chamber-associated immune deviation by TGF-beta2 treatment of monocytes isolated from Behcet's patients

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Immunomodulatory effects of interferon beta-1a in multiple sclerosis

1 reference

12 December 2020

Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Multiple sclerosis: trapped in deadly glue

1 reference

12 December 2020

Interferon beta induces T-helper 2 immune deviation in MS

1 reference

12 December 2020

Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes

1 reference

12 December 2020

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

12 December 2020

Whole genome analysis of the action of interferon-beta.

1 reference

12 December 2020

Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression

1 reference

12 December 2020

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

12 December 2020

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA

1 reference

12 December 2020

IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells

1 reference

12 December 2020

Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up

1 reference

12 December 2020

Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype

1 reference

12 December 2020

A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group

1 reference

12 December 2020

Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice

1 reference

12 December 2020

Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis

1 reference

12 December 2020